Mercury Pharmaceuticals UK

Welcome to Mercury Pharmaceuticals

We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.

More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.

OUR Science

The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.

Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.

Health Technology Assessment

The process of bringing your healthcare innovation to the market is lengthy and complicated. Besides the clinical or humanistic value that your product generates, for example by decreasing complication rate, prolonging survival, improving patient flow, the economic value needs to be demonstrated to healthcare payers.

STAY INFORMED!

Sep 2026

Stricter glucose control may affect quality of life in people living with diabetes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows that, in people living with diabetes (type 1 or 2) using data from continuous glucose monitoring (CGM) devices paired with daily quality-of-life ratings, days with more widely fluctuating glucose readings (while still within safe limits) are followed by days with a better quality life compared to days with more stricter control– suggesting the burden of that stricter control could be preventing those individuals with stricter control from enjoying various activities.

Sep 2026

Distinct EFEMP1 variants cause different forms of vision loss

Scientists identified a new vision condition linked to a gene already connected to a different vision-loss disease. While the previously identified disease causes loss of central vision, the new condition affects peripheral and night vision.

Sep 2026

Rare cortical neurons actively promote the transition into sleep

What makes the brain fall asleep? For nearly a century, scientists have looked to structures deep within the brain for the answer.

Sep 2026

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard treatment options.

Why Us?

Welcome to Mercury Pharmaceuticals

OUR Science

Health Services & Systems Research

Health Technology Assessment

Health Innovation Assessment Consultancy

MERCURY trials

Cancer

Neuroscience

STAY INFORMED!

Stricter glucose control may affect quality of life in people living with diabetes

Distinct EFEMP1 variants cause different forms of vision loss

Rare cortical neurons actively promote the transition into sleep

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

Why Us?

KNOWLEDGE OF RESEARCH ENVIRONMENT

UNDERSTANDING INDUSTRIAL NEEDS

FOCUSED PROJECT MANAGEMENT

INVESTMENT CAPABILITY